Skip to main content
. 2022 Sep 5;65:101590. doi: 10.1016/j.molmet.2022.101590

Figure 7.

Figure 7

The anti-lipemic effects of portal and nodose ganglia GLP-1R activation are abrogated in a novel GLP-1R KO hamster model.A-H: GLP-1R KO hamsters or WT littermate controls were fasted for 16 h then received portal vein injections of either GLP-1(7-36) (10 μg/kg) or vehicle (PBS). I-P: Alternatively, GLP-1R KO hamsters or WT littermate controls received bilateral nodose ganglia injections of GLP-1(7-36) (1ug in 1 μl PBS) or Vehicle (1 μl PBS). After treatment all hamsters were fat loaded with an oral gavage of olive oil (200 μl) and then given an IP injection of Pluronic F-127 (2  g/kg). Blood was then drawn over a 6 h period via retro-orbital bleeds. (A/I) Plasma TG, (B/J) plasma TG AUC, (C/K) plasma cholesterol, (D/L) plasma cholesterol AUC, (E/M) TRL TG, (F/N) TRL TG AUC, (G/O) TRL cholesterol, (H/P) TRL cholesterol AUC. Data is presented as means ± SEM (A-H: n=5–6/group; I–P: n=5–7/group). (∗P < 0.05, ∗∗P < 0.01, ∗∗∗∗P < 0.0001). ∗; WT_Veh vs. WT_GLP-1, ˆ; KO_Veh vs. WT_GLP-1, $; KO_GLP-1 vs. WT_GLP-1.